Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide.
In: Nucleosides, Nucleotides & Nucleic Acids, Jg. 29 (2010-02-01), Heft 2, S. 97-112
Online
academicJournal
Zugriff:
Survivin plays an important role in preventing apoptosis and permitting mitosis, and is highly expressed in various human cancers. EZN-3042 is a locked nucleic acid antisense oligonucleotide (LNA-AsODN) against survivin. We report the effects of EZN-3042 in animal models. In a chemical-induced liver regeneration model, treatment with a mouse homolog of EZN-3042 resulted in 80% down-modulation of survivin mRNA. In A549 and Calu-6 lung xenograft models, treatment with EZN-3042 single agent induced 60% down-modulation of survivin mRNA in tumors and 37-45% tumor growth inhibition (TGI). In Calu-6 model, when EZN-3042 was combined with paclitaxel, an 83% TGI was obtained. EZN-3042 is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with docetaxel. [ABSTRACT FROM AUTHOR]
| Titel: |
Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide.
|
|---|---|
| Autor/in / Beteiligte Person: | Sapra, Puja ; Wang, Maoliang ; Bandaru, Raj ; Zhao, Hong ; Greenberger, LeeM. ; Horak, IvanD. |
| Link: | |
| Zeitschrift: | Nucleosides, Nucleotides & Nucleic Acids, Jg. 29 (2010-02-01), Heft 2, S. 97-112 |
| Veröffentlichung: | 2010 |
| Medientyp: | academicJournal |
| ISSN: | 1525-7770 (print) |
| DOI: | 10.1080/15257771003597733 |
| Schlagwort: |
|
| Sonstiges: |
|